LATEST NEWS
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
The Vision Behind ENDRA
ENDRA Life Sciences (NASDAQ: NDRA) is a medical technology company pioneering advancements in ultrasound imaging. Its flagship innovation, the Thermo-Acoustic Enhanced Ultrasound (TAEUS) system, provides clinicians with real-time, cost-effective insights into tissue composition, starting with liver fat quantification for Non-Alcoholic Fatty Liver Disease (NAFLD).
Unlike MRI or biopsy, which can be expensive and invasive, ENDRA’s TAEUS technology aims to make liver assessment accessible in everyday healthcare settings. By integrating with more than 250,000 ultrasound systems already in use worldwide, ENDRA expands the capabilities of a trusted medical tool to deliver new diagnostic information at the point of care.
Led by a team with deep experience in imaging, healthcare innovation, and commercialization, ENDRA Life Sciences is working to transform how clinicians evaluate and manage chronic liver conditions.
5 Reasons Why ENDRA Life Sciences Could Be Positioned to Impact the Future of Diagnostic Imaging
How Does TAEUS Work?
Radiofrequency Energy Stimulation
TAEUS sends small pulses of radiofrequency energy into the body to gently excite tissue at the molecular level.
Ultrasound Detection
An ultrasound transducer then detects the resulting sound waves, translating them into detailed information about tissue composition.
Image Integration
The system overlays this data onto conventional ultrasound images, giving clinicians a clearer, more complete view of what’s happening inside the body.
Why Measure Liver Fat?
Excess fat buildup in the liver, known as steatosis, is the underlying cause of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) — conditions that together affect more than one billion people worldwide.
NAFLD and NASH are silent yet serious liver conditions that often show no symptoms until it’s too late. While both can be reversed if detected early, they can progress into advanced fibrosis, cirrhosis, or even liver cancer when left unchecked. Early detection is absolutely critical identifying these diseases in their earliest stages could make the difference between full recovery and irreversible damage.
Introducing the Management Team of ENDRA Life Sciences (NASDAQ: NDRA)
ENDRA is led by a management team and board of directors with substantial experience across medical imaging, diagnostics development, and corporate governance. The leadership group includes individuals with backgrounds in global healthcare technology, regulatory affairs, imaging innovation, and financial management.
Alexander Y. Tokman — Chief Executive Officer & Director
Mr. Tokman has served on ENDRA Life Sciences’ Board of Directors since 2008 and was appointed Chief Executive Officer in 2024. He is currently CEO-in-Residence at the Allen Institute for Artificial Intelligence (AI2).
From 2006 to 2017, Mr. Tokman served as President, Chief Executive Officer, and Director of Microvision, Inc., a publicly traded laser beam scanning projection and imaging company. Prior to that, he spent over a decade at GE Healthcare, where he held several global leadership roles, most recently as General Manager of its Global Molecular Imaging and Radiopharmacy business unit. During his tenure at GE, he led the definition and commercialization of key product lines, including PET/CT, which achieved more than $500 million in revenue within its first three years.
Earlier in his career, Mr. Tokman worked at Tracor Applied Sciences, where he led development programs and regional initiatives. He holds both bachelor’s and master’s degrees in Electrical Engineering from the University of Massachusetts, Dartmouth, and is a certified Six Sigma and Design for Six Sigma (DFSS) Master Black Belt.
Michael Thornton — Chief Technology Officer
Mr. Thornton has served as ENDRA Life Sciences’ Chief Technology Officer since 2007. Before joining the company, he founded and led Enhanced Vision Systems Corp. (EVS), a developer of medical imaging equipment for the pharmaceutical, biotechnology, and academic sectors.
After EVS was acquired by General Electric Company in 2002, Mr. Thornton held several leadership roles at GE Healthcare, including Global Product Manager and Site Leader, where he helped expand the pre-clinical imaging business into CT, optical, and PET technologies with international reach.
He also co-founded Volumetrics Medical Corp., a developer of quality assurance devices for diagnostic imaging. Mr. Thornton holds a master’s degree in Electrical Engineering from the University of Western Ontario and a bachelor’s degree in electrical engineering from the University of Toronto.
Richard Jacroux — Chief Financial Officer
Mr. Jacroux was appointed Chief Financial Officer of ENDRA Life Sciences in 2024. He brings more than 20 years of experience in financial management, accounting, and business operations. Before joining ENDRA, he served as Chief Financial Officer for several technology companies and founded Impact Solve, LLC, a firm providing accounting and fractional CFO services.
Earlier in his career, Mr. Jacroux worked at Ernst & Young LLP and has since developed extensive experience in strategic planning and financial oversight for growth-stage companies. He holds a bachelor’s degree in Business Administration and Accounting from the University of Washington and an MBA from the Kellogg School of Management.
Ziad Rouag — Head of Regulatory & Clinical Affairs
Mr. Rouag oversees ENDRA Life Sciences’ regulatory strategy and clinical development programs. He brings decades of experience in medical device regulation, clinical operations, and product commercialization. Prior to joining ENDRA, he held executive roles in medical technology companies, guiding multiple imaging and diagnostic systems through the FDA and CE approval process. His background reflects a strong focus on advancing medical technologies from development to clinical adoption.
Idan Steinberg — Head of Engineering
Mr. Steinberg leads ENDRA Life Sciences’ engineering initiatives, overseeing product design, development, and system integration. He has extensive experience in ultrasound and imaging system engineering, with a focus on translating innovative research into commercially viable technologies. His technical expertise supports ENDRA’s goal of delivering reliable, high-performance imaging solutions for clinical use.
Scott Sober — Head of Operations
Mr. Sober manages operational planning and process optimization at ENDRA Life Sciences. His background includes leadership roles in operations, supply chain, and production within healthcare technology organizations. He is responsible for supporting product development and manufacturing efficiency as the company advances its imaging platform toward broader market adoption.
Sources
- Source 1: https://endrainc.com/
- Source 2: https://www.biospace.com/press-releases/endra-life-sciences-provides-a-business-update-and-reports-first-quarter-2025-financial-results
- Source 3: https://www.ainvest.com/news/endra-life-sciences-reports-q2-2025-financial-results-cuts-operating-expenses-42-advances-taeus-liver-system-development-2508
- Source 4: https://www.streetinsider.com/Business%2BWire/ENDRA%2BLife%2BSciences%2BCloses%2BUp%2Bto%2B%2414.4%2BMillion%2BPrivate%2BPlacement%2Band%2BLaunches%2BCrypto%2BTreasury%2BStrategy%2Bwith%2B%243%2BMillion%2Bin%2BInitial%2BHYPE%2BToken%2BHoldings/25491557.html
- Source 6: https://endrainc.com/taeus/future-applications
- Source 7: https://endrainc.com/taeus/future-applications
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Compensation: Pursuant to an agreement between Virtus Media Group LLC and The Investing Authority, Virtus Media Group LLC has been hired by The Investing Authority to publicly disseminate information about NASDAQ: NDRA via digital communication s beginning 2025-11-17 and ending 2026-1-12. We have been paid $75,000 USD. Social media influencer compensation: Virtus Media Group has paid Influencer #1 $50 to publicly disseminate information about NASDAQ: NDRA via digital communications. Virtus Media Group has paid the Investing Authority $7,500 to publicly disseminate information about NASDAQ: NDRA via digital communications. ENDRA Life Sciences has paid us $75,000 USD.
